Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C24H21ClF3NO4S |
| Molecular Weight | 511.941 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H](N(C1=C(F)C=CC(F)=C1)S(=O)(=O)C2=CC=C(Cl)C=C2)C3=C(CCCC(O)=O)C=C(F)C=C3
InChI
InChIKey=IZAOBRWCUGOKNH-OAHLLOKOSA-N
InChI=1S/C24H21ClF3NO4S/c1-15(21-11-7-18(26)13-16(21)3-2-4-24(30)31)29(23-14-19(27)8-12-22(23)28)34(32,33)20-9-5-17(25)6-10-20/h5-15H,2-4H2,1H3,(H,30,31)/t15-/m1/s1
| Molecular Formula | C24H21ClF3NO4S |
| Molecular Weight | 511.941 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/25710492 | https://www.ncbi.nlm.nih.gov/pubmed/15452193Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/15670587
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25710492 | https://www.ncbi.nlm.nih.gov/pubmed/15452193
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/15670587
BMS-299897 is an orally bioavailable, sulfonamide γ-secretase inhibitor with an IC50 of 7 nM for Aβ production inhibition in HEK293 cells stably overexpressing amyloid precursor protein (APP). BMS-299897 has the potential for treatment of Alzheimer's disease.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15670587 | https://www.ncbi.nlm.nih.gov/pubmed/25291315
Curator's Comment: BMS-299897 markedly reduced both brain and plasma Abeta(1-40) in APP-YAC mice and in guinea pigs. Readily crosses blood–brain barrier.
Originator
Sources: http://adisinsight.springer.com/drugs/800021454
Curator's Comment: # Bristol-Myers Squibb
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
4740 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19480557/ |
30 mg/kg single, oral dose: 30 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
BMS-299897 plasma | Mus musculus population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
4037 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19480557/ |
15 mg/kg single, oral dose: 15 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
BMS-299897 plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
3232 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19480557/ |
15 mg/kg single, oral dose: 15 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
BMS-299897 plasma | Cavia porcellus population: HEALTHY age: ADULT sex: MALE food status: FED |
|
1629 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19480557/ |
25 mg/kg single, oral dose: 25 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
BMS-299897 plasma | Macaca fascicularis population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
4014 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19480557/ |
3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
BMS-299897 plasma | Mus musculus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
9685 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19480557/ |
30 mg/kg single, oral dose: 30 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
BMS-299897 plasma | Mus musculus population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
27478 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19480557/ |
15 mg/kg single, oral dose: 15 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
BMS-299897 plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
7400 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19480557/ |
3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
BMS-299897 plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
16778 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19480557/ |
15 mg/kg single, oral dose: 15 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
BMS-299897 plasma | Cavia porcellus population: HEALTHY age: ADULT sex: MALE food status: FED |
|
3341 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19480557/ |
3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
BMS-299897 plasma | Cavia porcellus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
6835 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19480557/ |
5 mg/kg single, intravenous dose: 5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
BMS-299897 plasma | Macaca fascicularis population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
8309 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19480557/ |
25 mg/kg single, oral dose: 25 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
BMS-299897 plasma | Macaca fascicularis population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
12 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19480557/ |
3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
BMS-299897 plasma | Mus musculus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
5.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19480557/ |
3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
BMS-299897 plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
18 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19480557/ |
3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
BMS-299897 plasma | Cavia porcellus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
9.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19480557/ |
5 mg/kg single, intravenous dose: 5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
BMS-299897 plasma | Macaca fascicularis population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.5% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19480557/ |
3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
BMS-299897 plasma | Mus musculus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
0.5% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19480557/ |
15 mg/kg single, oral dose: 15 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
BMS-299897 plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| A γ-secretase inhibitor, but not a γ-secretase modulator, induced defects in BDNF axonal trafficking and signaling: evidence for a role for APP. | 2015 |
|
| Advances in recent patent and clinical trial drug development for Alzheimer's disease. | 2014-07 |
|
| Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897. | 2005-02-15 |
|
| Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor. | 2005-02 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15670587
Mice: 100 mg/kg po, guinea pigs: 30 mg/kg intraperitoneally
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25710492
At ∼1.0 uM, BMS-299897 decreased Aβ42, Aβ40 and Aβ38 peptides to levels ranging from 20 to 50% of the vehicle control in rat neuronal cultures.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 08:02:22 GMT 2025
by
admin
on
Wed Apr 02 08:02:22 GMT 2025
|
| Record UNII |
QK855F579S
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
11249248
Created by
admin on Wed Apr 02 08:02:22 GMT 2025 , Edited by admin on Wed Apr 02 08:02:22 GMT 2025
|
PRIMARY | |||
|
DTXSID50460039
Created by
admin on Wed Apr 02 08:02:22 GMT 2025 , Edited by admin on Wed Apr 02 08:02:22 GMT 2025
|
PRIMARY | |||
|
QK855F579S
Created by
admin on Wed Apr 02 08:02:22 GMT 2025 , Edited by admin on Wed Apr 02 08:02:22 GMT 2025
|
PRIMARY | |||
|
290315-45-6
Created by
admin on Wed Apr 02 08:02:22 GMT 2025 , Edited by admin on Wed Apr 02 08:02:22 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
IC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |